An in-silico model for predicting the erythropoietic response to the novel EPO dimer PT-401.

被引:0
|
作者
Kabrun, N. [1 ]
Handelin, B. L. [1 ]
Gomez, H. J. [1 ]
Herren, L. T. [1 ]
机构
[1] DNAPrint Genom Inc, Sarasota, FL USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:S96 / S96
页数:1
相关论文
共 41 条
  • [21] Efficacy assessment of novel methanimine derivatives in chronic constriction injury-induced neuropathic model: An in-vivo, ex-vivo and In-Silico approach
    Khan, Jawad
    Ali, Gowhar
    Saeed, Aamer
    Khurshid, Asma
    Ahmad, Sajjad
    Kashtoh, Hamdy
    Ataya, Farid S.
    Bathiha, Gaber El-Saber
    Ullah, Aman
    Khan, Ajmal
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 198
  • [22] Predicting the influence of multiple components on microbial inhibition using a logistic response model - a novel approach
    Henley-Smith, Cynthia J.
    Steffens, Francois E.
    Botha, Francien S.
    Lall, Namrita
    [J]. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14
  • [23] Predicting the influence of multiple components on microbial inhibition using a logistic response model - a novel approach
    Cynthia J Henley-Smith
    Francois E Steffens
    Francien S Botha
    Namrita Lall
    [J]. BMC Complementary and Alternative Medicine, 14
  • [24] Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining
    Vougas, Konstantinos
    Sakellaropoulos, Theodore
    Kotsinas, Athanassios
    Foukas, George-Romanos P.
    Ntargaras, Andreas
    Koinis, Filippos
    Polyzos, Alexander
    Myrianthopoulos, Vassilios
    Zhou, Hua
    Narang, Sonali
    Georgoulias, Vassilis
    Alexopoulos, Leonidas
    Aifantis, Iannis
    Townsend, Paul A.
    Sfikakis, Petros
    Fitzgerald, Rebecca
    Thanos, Dimitris
    Bartek, Jiri
    Petty, Russell
    Tsirigos, Aristotelis
    Gorgoulis, Vassilis G.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2019, 203
  • [25] In-Silico Discovery of Novel Small-Molecule Inhibitors Targeting Transgelin-2-Actin Interaction Inhibits Proliferation, Invasion and Improves Chemo-Radiation Response in Human Glioblastoma
    Kumar, A.
    Rajasekera, P.
    Biehn, S.
    Beyer, S.
    McElroy, J.
    Becker, A.
    Johnson, B.
    Cui, T.
    Sebastian, E.
    Grosu, A.
    Lindert, S.
    Bell, E. H.
    Haque, S. J.
    Chakravarti, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E593 - E593
  • [26] Anoikis Patterns in Cervical Cancer: Identification of Subgroups and Construction of a Novel Risk Model for Predicting Prognosis and Immune Response
    Xiang, Xuesong
    Ding, Jingxin
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (11):
  • [27] A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma
    Akinari Kasai
    Jinsei Miyoshi
    Yasushi Sato
    Koichi Okamoto
    Hiroshi Miyamoto
    Takashi Kawanaka
    Chisato Tonoiso
    Masafumi Harada
    Masakazu Goto
    Takahiro Yoshida
    Akihiro Haga
    Tetsuji Takayama
    [J]. Scientific Reports, 14
  • [28] A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma
    Kasai, Akinari
    Miyoshi, Jinsei
    Sato, Yasushi
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Kawanaka, Takashi
    Tonoiso, Chisato
    Harada, Masafumi
    Goto, Masakazu
    Yoshida, Takahiro
    Haga, Akihiro
    Takayama, Tetsuji
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01)
  • [29] Identification of a Novel Model for Predicting the Prognosis and Immune Response Based on Genes Related to Cuproptosis and Ferroptosis in Ovarian Cancer
    Li, Ying
    Fang, Tian
    Shan, Wanying
    Gao, Qinglei
    [J]. CANCERS, 2023, 15 (03)
  • [30] A Novel KIF4A-related Model for Predicting Immunotherapy Response and Prognosis in Kidney Renal Clear Cell Carcinoma
    Yang, Guang Hua
    Dong, Xu
    Wei, Xi Feng
    Liu, Ran Lu
    Wang, Chao
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2024,